The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
2021 · Clinical Lung Cancer · 27 citations
https://doi.org/10.1016/j.cllc.2021.08.012
H
Hirva Mamdani
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
263
Papers
1.9K
Citations
23
h-index
44
i10-index
Hirva Mamdani is an academic researcher from Wayne State University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Research Studies. The author has an h-index of 23, co-authored 224 publications.
ORCID: 0000-0003-3874-8703Papers by this author
worksRisk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer
2021 · Clinical Lung Cancer · 15 citations
https://doi.org/10.1016/j.cllc.2021.04.004
Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
2021 · Lung Cancer · 13 citations
https://doi.org/10.1016/j.lungcan.2021.08.010
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
2025 · Nature Communications · 11 citations
https://doi.org/10.1038/s41467-024-55092-2
Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer (NSCLC): Big Ten Cancer Research Consortium LUN16-081
2025 · Journal for ImmunoTherapy of Cancer · 6 citations
https://doi.org/10.1136/jitc-2024-010316
Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non–Small-Cell Lung Cancer
2024 · JCO Precision Oncology · 2 citations
https://doi.org/10.1200/po.23.00371
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat